XERESE 5 % — DIN 02404044
ACYCLOVIR : 5 % HYDROCORTISONE : 1 % · BAUSCH HEALTH, CANADA INC. · CREAM · wholesale supply in Canada
Health Canada status: MARKETED
What is XERESE?
XERESE 5 % contains ACYCLOVIR : 5 % HYDROCORTISONE : 1 %. It is listed in the Health Canada Drug Product Database under DIN 02404044, held by BAUSCH HEALTH, CANADA INC., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 30-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XERESE used for?
XERESE (acyclovir 5% and hydrocortisone 1%) Topical Cream, is indicated for the treatment of early signs and symptoms of recurrent herpes labialis (cold sores) to reduce the progression of cold sore episodes to ulcerative lesions in immunocompetent adults and adolescents (12 years of age and older).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 % |
|---|---|
| Dosage form | CREAM |
| Route | TOPICAL |
| Pack configuration (monograph) | 5 g tube, 0.5 g foil pouch |
| Storage | Store at controlled room temperature 20° - 25° C; excursions permitted to 15 - 30° C. Do not freeze. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Aciclovir, Combinations |
|---|---|
| ATC code | D06BB53 |
| AHFS class | 84:06.00 ; 84:04.06 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02404044 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2404044 |
| Brand name | XERESE |
| Generic / active ingredient | ACYCLOVIR : 5 % HYDROCORTISONE : 1 % |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | D06BB53 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D06BB |
| Current status | MARKETED |
| Status date | 30-Dec-2020 |
| Original market date | 2013-07-26 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply topically to all lesions 5 times per day for 5 days. Initiate therapy as early as possible after first signs or symptoms.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to acyclovir, valacyclovir, hydrocortisone or any component. Untreated infections of bacterial, viral, tuberculous or fungal origin.
Warnings and precautions
For external use only. Not for eyes, mouth, nose, or genitals. Risk of HPA axis suppression, Cushing's syndrome, visual disturbances, and skin atrophy with prolonged/occlusive use.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC D06BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Imiquimod | ALDARA P · APO-IMIQUIMOD · IMIQUIMOD · TARO-IMIQUIMOD · TARO-IMIQUIMOD PUMP · VYLOMA · ZYCLARA | 8 | 4 | Yes |
| Aciclovir | APO-ACYCLOVIR OINTMENT · MINT-ACYCLOVIR OINTMENT · TARO-ACYCLOVIR · ZOVIRAX | 5 | 4 | Yes |
| Aciclovir, Combinations | XERESE | 1 | 1 | Yes |
| Sinecatechins | VEREGEN | 1 | 1 | Yes |
| Podophyllotoxin | CONDYLINE · PODOFILM LIQ 250MG/ML · WARTEC | 3 | 0 | Not in Canada |
| Idoxuridine | HERPLEX D · SANDOZ IDOXURIDINE | 2 | 0 | Not in Canada |
| Penciclovir | DENAVIR | 1 | 0 | Not in Canada |
| Edoxudine | VIROSTAT CREAM 3% | 1 | 0 | Not in Canada |
| Podophyllin, Combinations | VERBAN ONT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D06B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D06BX | Ingenol Mebutate · Metronidazole · Other Chemotherapeutics | 9 | 3 |
| D06BA | Mafenide · Silver Sulfadiazine · Silver Sulfadiazine, Combinations | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.